A Phase 1 Study of COTI-2 for the Treatment of Advanced or Recurrent Gynecologic Malignancies

Trial Profile

A Phase 1 Study of COTI-2 for the Treatment of Advanced or Recurrent Gynecologic Malignancies

Recruiting
Phase of Trial: Phase I

Latest Information Update: 15 Nov 2017

At a glance

  • Drugs COTI 2 (Primary)
  • Indications Cervical cancer; Endometrial cancer; Fallopian tube cancer; Gynaecological cancer; Head and neck cancer; Ovarian cancer; Peritoneal cancer
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Sponsors Critical Outcome Technologies
  • Most Recent Events

    • 15 Nov 2017 Pharmacokinetic data from gynecological malignancies arm published in the Critical Outcome Technologies Media Release.
    • 11 Oct 2017 According to a Critical Outcome Technologies media release, the first patient has been dosed in the head and neck squamous cell carcinoma (HNSCC) arm of this trial at a dosage level of 1.0 mg/kg.
    • 28 Aug 2017 According to an Critical Outcome Technologies media release, company expects to initiate expansion arms evaluating COTI-2 as combination treatment in gynecological malignancies and HNSCC in 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top